

Review article: loss of response to anti-TNF treatments

Alimentary Pharmacology and Therapeutics  
33, 987-995

DOI: [10.1111/j.1365-2036.2011.04612.x](https://doi.org/10.1111/j.1365-2036.2011.04612.x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Infliximab to treat Crohn's disease: an update. Clinical and Experimental Gastroenterology, 2011, 4, 227.	2.3	13
2	Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy, 2012, 4, 883-898.	2.0	81
3	Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease. European Journal of Clinical Nutrition, 2012, 66, 1219-1223.	2.9	37
4	Anti-TNF trough levels and detection of antibodies to anti-TNF in inflammatory bowel disease: are they ready for everyday clinical use?. Expert Opinion on Biological Therapy, 2012, 12, 179-192.	3.1	26
5	Phase I Clinical Trial of Smad7 Knockdown Using Antisense Oligonucleotide in Patients With Active Crohn's Disease. Molecular Therapy, 2012, 20, 870-876.	8.2	125
7	Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflammatory Bowel Diseases, 2012, 18, 1628-1633.	1.9	78
8	Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflammatory Bowel Diseases, 2012, 18, 2026-2033.	1.9	118
9	The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Alimentary Pharmacology and Therapeutics, 2012, 35, 714-722.	3.7	53
10	Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis. American Journal of Gastroenterology, 2013, 108, 40-47.	0.4	298
11	Nutritional Management of Inflammatory Bowel Disease and Short Bowel Syndrome. , 2013, , 739-756.		1
12	A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab. Clinical Gastroenterology and Hepatology, 2013, 11, 654-666.	4.4	168
13	NS6180, a new $Ca^{2+}$ channel inhibitor prevents $T$ -cell activation and inflammation in a rat model of inflammatory bowel disease. British Journal of Pharmacology, 2013, 168, 432-444.	5.4	60
14	Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 4521-4536.	6.4	72
15	Addition of thiopurines can recapture response in patients with Crohn's disease who have lost response to anti-tumor necrosis factor monotherapy. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1595-1599.	2.8	39
16	Efficacy of anti-TNF-alpha monoclonal antibodies in inflammatory bowel disease treatment. International Journal of Interferon, Cytokine and Mediator Research, 2013, , 11.	1.1	1
17	Practical Medical Management of Crohn's Disease. ISRN Gastroenterology, 2013, 2013, 1-12.	1.5	16
18	Taking Crohn's Disease Personally. Rambam Maimonides Medical Journal, 2013, 4, e0011.	1.0	1
19	Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 38, 447-459.	3.7	96

#	ARTICLE	IF	CITATIONS
20	Top-Down or Step-Up Treatment in Crohn's Disease?. Digestive Diseases, 2013, 31, 83-90.	1.9	48
21	Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn's disease?. Clinical and Experimental Gastroenterology, 2014, 7, 163.	2.3	23
22	Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 243-255.	17.8	165
23	Pretreatment 25-Hydroxyvitamin D Levels and Durability of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Diseases. Journal of Parenteral and Enteral Nutrition, 2014, 38, 385-391.	2.6	98
24	Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut, 2014, 63, 1721-1727.	12.1	336
25	Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: A systematic review and meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 1632-1641.	1.3	83
26	Genetic polymorphisms of tumour necrosis factor alpha (TNF) promoter gene and response to TNF inhibitors in Spanish patients with inflammatory bowel disease. International Journal of Immunogenetics, 2014, 41, 63-68.	1.8	32
27	Loss of Response to Anti-Tumor Necrosis Factors: What Is the Next Step?. Digestive Diseases, 2014, 32, 384-388.	1.9	31
28	Effects of Infliximab Retreatment After Consecutive Discontinuation of Infliximab and Adalimumab in Refractory Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 251-258.	1.9	24
29	Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2014, 20, 2247-2259.	1.9	232
30	Biological Therapy in a Pediatric Crohn Disease Population at a Referral Center. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 582-587.	1.8	32
31	Superficial abdominal thrombophlebitis (Mondor's disease) presenting as loss of response to adalimumab in a Crohn's disease patient. Journal of Crohn's and Colitis, 2014, 8, 1557-1558.	1.3	6
32	Predictors of response to Infliximab in children with luminal Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 739-746.	1.3	27
33	Review article: anti-adhesion therapies for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 579-594.	3.7	155
34	The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut, 2014, 63, 1258-1264.	12.1	266
35	Addressing current treatment challenges in Crohn's disease in real life: A physician's survey. Digestive and Liver Disease, 2014, 46, 1066-1071.	0.9	4
36	Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease. Gastroenterology Clinics of North America, 2014, 43, 457-478.	2.2	34
37	Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial. American Journal of Gastroenterology, 2014, 109, 1055-1064.	0.4	125

#	ARTICLE	IF	CITATIONS
38	Current and Future Status of Therapeutic Drug Monitoring in the Treatment of IBD. Current Treatment Options in Gastroenterology, 2014, 12, 76-89.	0.8	4
39	Su1392 Benefit of Infliximab Re-Introduction After Successive Failure of Infliximab and Adalimumab in Crohn's Disease. Gastroenterology, 2014, 146, S-456.	1.3	0
40	Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmunity Reviews, 2014, 13, 24-30.	5.8	322
41	PRISMAâ€”Efficacy and Safety of Vedolizumab for Inflammatory Bowel Diseases. Medicine (United Tj ETQq1 1 0.784314 rgBT /Overl	1.0	57
42	Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure. Medicine (United States), 2015, 94, e673.	1.0	16
43	Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of antiâ€”TNF therapy. Alimentary Pharmacology and Therapeutics, 2015, 42, 391-405.	3.7	99
44	Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays. Therapeutic Drug Monitoring, 2015, 37, 479-485.	2.0	37
45	Efficacy and Safety of Adalimumab 80 mg Weekly in Luminal Crohn's Disease. Inflammatory Bowel Diseases, 2015, 21, 1047-1053.	1.9	14
46	Magnetic resonance imagingâ€”quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2015, 42, 343-355.	3.7	46
47	Treatment Nonadherence in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2979-2984.	1.9	31
48	Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy. Inflammatory Bowel Diseases, 2015, 21, 1.	1.9	16
49	Managing refractory Crohn's disease: challenges and solutions. Clinical and Experimental Gastroenterology, 2015, 8, 131.	2.3	6
50	Fucoidan Extracts Ameliorate Acute Colitis. PLoS ONE, 2015, 10, e0128453.	2.5	89
51	Inflammatory Bowel Disease Patients Are Frequently Nonadherent to Scheduled Induction and Maintenance Infliximab Therapy: A Canadian Cohort Study. Canadian Journal of Gastroenterology and Hepatology, 2015, 29, 309-314.	1.9	12
52	Current stage in inflammatory bowel disease: What is next?. World Journal of Gastroenterology, 2015, 21, 11282.	3.3	24
53	Next-Generation Therapeutics for IBD. Current Gastroenterology Reports, 2015, 17, 21.	2.5	35
54	Molecular Analysis of Inflammatory Bowel Disease: Clinically Useful Tools for Diagnosis, Response Prediction, and Monitoring of Targeted Therapy. Molecular Diagnosis and Therapy, 2015, 19, 141-158.	3.8	7
55	Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment. European Journal of Clinical Pharmacology, 2015, 71, 773-799.	1.9	15

#	ARTICLE	IF	CITATIONS
56	Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1. <i>Journal of Biological Chemistry</i> , 2015, 290, 4022-4037.	3.4	63
58	Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 522-530.e2.	4.4	268
59	Benefit of Infliximab Reintroduction after Successive Failure of Infliximab and Adalimumab in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 349-355.	1.3	16
60	Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 379-386.	1.5	21
61	Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 613-623.	3.7	266
63	Particular aspects of proctology for anoperineal lesions in Crohn's disease. <i>Journal of Visceral Surgery</i> , 2015, 152, S45-S53.	0.8	4
64	The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 1110-1117.	1.5	40
65	Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease. <i>Journal of Gastroenterology</i> , 2015, 50, 758-768.	5.1	10
66	Significance of low level infliximab in the absence of anti-infliximab antibodies. <i>World Journal of Gastroenterology</i> , 2015, 21, 1907.	3.3	19
67	Role for Therapeutic Drug Monitoring During Induction Therapy with TNF Antagonists in IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 182-197.	1.9	182
68	Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy: a meta-analysis. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 168-175.	3.2	71
69	Azathioprine discontinuation earlier than 6 months in Crohn's disease patients started on anti-TNF therapy is associated with loss of response and the need for anti-TNF dose escalation. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 436-441.	1.6	19
70	Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 147-154.	2.5	14
71	Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1473-1479.	2.4	13
72	Recent insights into the molecular pathogenesis of Crohn's disease: a review of emerging therapeutic targets. <i>Clinical and Experimental Gastroenterology</i> , 2016, 9, 59.	2.3	25
73	Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. <i>Clinical and Experimental Gastroenterology</i> , 2016, Volume 9, 311-323.	2.3	7
74	Ustekinumab in treatment of Crohn's disease: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3685-3698.	4.3	38
75	Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1655-1661.	1.9	13

#	ARTICLE	IF	CITATIONS
76	Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison. <i>Pharmacotherapy</i> , 2016, 36, 861-869.	2.6	3
77	Efficacy and safety of vedolizumab in the treatment of ulcerative colitis. <i>Gastroenterology</i> & <i>Hepatology</i> (English Edition), 2016, 39, 677-686.	0.1	2
78	Unleashing the true potential of social networks: confirming infliximab medical trials through Facebook posts. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2016, 5, 1.	2.1	14
79	Therapeutic drug monitoring in inflammatory bowel disease. <i>Current Opinion in Pediatrics</i> , 2016, 28, 620-625.	2.0	12
81	Fate of Multimeric Oligomers, Submicron, and Micron Size Aggregates of Monoclonal Antibodies Upon Subcutaneous Injection in Mice. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 1693-1704.	3.3	19
82	Eficacia y seguridad de vedolizumab en el tratamiento de la colitis ulcerosa. <i>Gastroenterology</i> & <i>Hepatology</i> , 2016, 39, 677-686.	0.5	7
83	Drugs and anti-drug antibody levels in the management of patients with inflammatory bowel disease. <i>Gastroenterology</i> & <i>Hepatology</i> (English Edition), 2016, 39, 265-272.	0.1	1
84	A Retrospective Claims Database Study on Drug Utilization in Japanese Patients with Crohn's Disease Treated with Adalimumab or Infliximab. <i>Advances in Therapy</i> , 2016, 33, 1947-1963.	2.9	20
85	Are Immunosuppressants Becoming Obsolete?. <i>Digestive Diseases</i> , 2016, 34, 56-60.	1.9	2
86	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2016, 111, 1599-1607.	0.4	300
87	Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease – algorithm for practical management. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 30-51.	3.7	238
88	Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS5745 versus placebo for ulcerative colitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 157-169.	3.7	53
89	Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 673-683.	3.7	42
91	Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital. <i>Internal Medicine Journal</i> , 2016, 46, 1386-1391.	0.8	2
92	Research topic: Managing compassionate therapy – the role of the virtual clinic. <i>Journal of Gastroenterology and Hepatology</i> (Australia), 2016, 31, 44-45.	2.8	1
93	The Role of Laboratory Tests in Crohn's Disease. <i>Clinical Medicine Insights Gastroenterology</i> , 2016, 9, CGast.S38203.	1.0	27
94	Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1277-1290.	3.1	42
95	Mean Platelet Volume in Crohn's Disease Patients Predicts Sustained Response to a 52-Week Infliximab Therapy: A Pilot Study. <i>Digestive Diseases and Sciences</i> , 2016, 61, 542-549.	2.3	16

#	ARTICLE	IF	CITATIONS
96	Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease. Digestive and Liver Disease, 2016, 48, 360-370.	0.9	34
97	Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study. Journal of Crohn's and Colitis, 2016, 10, 549-555.	1.3	70
98	Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease. Expert Opinion on Investigational Drugs, 2016, 25, 263-273.	4.1	25
99	Vedolizumab in the treatment of Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 283-290.	3.0	12
100	Monitoring Crohn's disease during anti-TNF- $\alpha$ therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard. European Radiology, 2016, 26, 2107-2117.	4.5	33
101	Use of anti-TNF drug levels to optimise patient management. Frontline Gastroenterology, 2016, 7, 289-300.	1.8	88
102	Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease. Expert Review of Clinical Pharmacology, 2016, 9, 429-439.	3.1	40
103	Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clinical and Translational Gastroenterology, 2016, 7, e135.	2.5	473
104	Anti-TNF- $\alpha$ therapies for the treatment of Crohn's disease: the past, present and future. Expert Opinion on Investigational Drugs, 2016, 25, 129-143.	4.1	48
105	Clinical relevance and inter-test reliability of anti-infliximab antibodies and infliximab trough levels in patients with inflammatory bowel disease. Digestive and Liver Disease, 2016, 48, 138-143.	0.9	18
106	Laboratory Tests in Crohn's Disease. , 2016, , 15-30.		0
107	Optimizing biological therapy in Crohn's disease. Expert Review of Gastroenterology and Hepatology, 2016, 10, 37-45.	3.0	14
108	Biologics and biosimilars in IBD – the road to personalized treatment. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 74-76.	17.8	6
109	Next generation of small molecules in inflammatory bowel disease. Gut, 2017, 66, 199-209.	12.1	122
110	Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis. European Journal of Clinical Nutrition, 2017, 71, 773-777.	2.9	34
111	Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1128-1134.	3.7	106
112	Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista De Gastroenterología De México (English Edition), 2017, 82, 46-84.	0.2	7
113	Utilisation of anti-TNF levels in a UK tertiary IBD centre. Frontline Gastroenterology, 2017, 8, 189-195.	1.8	2



#	ARTICLE	IF	CITATIONS
114	Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1135-1145.	3.7	40
115	JAK inhibition in inflammatory bowel disease. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 693-703.	3.0	70
116	Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1580-1588.e3.	4.4	181
117	Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres. <i>Frontline Gastroenterology</i> , 2017, 8, 196-202.	1.8	41
118	Autologous Stem Cell Transplantation for Refractory Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1157-1158.	1.3	0
119	Anti-TNF Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 791-797.	1.9	13
120	Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 597-606.	1.4	22
121	Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab. <i>Digestive and Liver Disease</i> , 2017, 49, 163-169.	0.9	15
122	The PROSIT-BIO Cohort. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 233-243.	1.9	116
123	Tacrolimus Exerts Only a Transient Effectiveness in Refractory Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2017, 64, 721-725.	1.8	7
124	Colonic Phenotypes Are Associated with Poorer Response to Anti-TNF Therapies in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1382-1393.	1.9	22
125	Therapeutic drug monitoring of anti-tumour necrosis factor- $\alpha$ agents in inflammatory bowel disease. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 303-317.	2.4	25
126	The biologics of ulcerative colitis. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 175-184.	3.1	12
127	Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. <i>Revista De Gastroenterología De México</i> , 2017, 82, 46-84.	0.2	22
128	Ustekinumab en el tratamiento de la enfermedad de Crohn. <i>Gastroenterología Y Hepatología</i> , 2017, 40, 688-698.	0.5	13
129	Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1037-1053.	3.7	225
130	Efficacy and safety of golimumab in Crohn's disease: a French national retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 1077-1084.	3.7	23
131	Patients with Crohn's Disease with High Body Mass Index Present More Frequent and Rapid Loss of Response to Infliximab. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1853-1859.	1.9	23



#	ARTICLE	IF	CITATIONS
132	Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn's Disease: A Hospital-Based Cohort Study from Korea. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2882-2893.	2.3	12
133	Exploring the Use of a Participative Design in the Early Development of a Predictive Test: The Importance of Physician Involvement. <i>Public Health Genomics</i> , 2017, 20, 174-187.	1.0	4
134	Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2017, 49, 1086-1091.	0.9	23
135	Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 603-626.	2.2	47
136	Update on Therapeutic Drug Monitoring in Crohn's Disease. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 645-659.	2.2	11
137	A novel function of CXCL10 in mediating monocyte production of proinflammatory cytokines. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1271-1280.	3.3	49
138	Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2017, 153, 858-859.	1.3	18
139	Editorial: anti-tumor necrosis factor $\alpha$ antibodies "can efficacy be regained?". <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1473-1474.	3.7	1
140	Optimizing Inflammatory Bowel Disease Management. <i>Gastroenterology Nursing</i> , 2017, 40, S1-S14.	0.4	0
141	Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1555-1565.	1.9	21
142	Therapeutic Drug Monitoring in Inflammatory Bowel Disease. <i>Pediatric Clinics of North America</i> , 2017, 64, 1309-1326.	1.8	12
143	Therapeutic efficacy of a combined sage and bitter apple phytopharmaceutical in chronic DSS-induced colitis. <i>Scientific Reports</i> , 2017, 7, 14214.	3.3	9
144	Novel therapeutic targets for inflammatory bowel disease. <i>Journal of Autoimmunity</i> , 2017, 85, 103-116.	6.5	88
145	Comparisons of Serum Infliximab and Antibodies-to-Infliximab Tests Used in Inflammatory Bowel Disease Clinical Trials of Remicade <sup>®</sup> . <i>AAPS Journal</i> , 2017, 19, 161-171.	4.4	57
146	Can Thiopurines Prevent Formation of Antibodies Against Tumor Necrosis Factor Antagonists After Failure of These Therapies?. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 76-78.	4.4	0
147	Anti TNF- $\alpha$ therapy for ulcerative colitis: current status and prospects for the future. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 223-233.	3.0	78
148	Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. <i>Digestive Diseases</i> , 2017, 35, 423-432.	1.9	5
149	Ustekinumab to treat Crohn's disease. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2017, 40, 688-698.	0.1	4

#	ARTICLE	IF	CITATIONS
150	Frontiers in Drug Research and Development for Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2017, 8, 400.	3.5	40
151	Practical recommendations for the use of therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. <i>Clinical Pharmacology: Advances and Applications</i> , 2017, Volume 9, 101-111.	1.2	27
152	Anti-NKG2D mAb: A New Treatment for Crohn's Disease?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1997.	4.1	23
153	Efficacy and Safety of Dose Escalation to Adalimumab 80 mg Every Other Week in Japanese Patients with Crohn's Disease Who Lost Response to Maintenance Therapy. <i>Inflammatory Intestinal Diseases</i> , 2017, 2, 228-235.	1.9	12
154	PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1276.	4.1	47
155	Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-24.	1.2	32
156	Second Korean guidelines for the management of Crohn's disease. <i>Intestinal Research</i> , 2017, 15, 38.	2.6	39
157	Nutritional Management of Inflammatory Bowel Disease and Short Bowel Syndrome. , 2017, , 857-874.		3
158	A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 113-121.	2.0	10
160	Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 575.	4.1	20
161	A bispecific antibody that targets IL-6 receptor and IL-17A for the potential therapy of patients with autoimmune and inflammatory diseases. <i>Journal of Biological Chemistry</i> , 2018, 293, 9326-9334.	3.4	22
162	Review article: novel oral-targeted therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1610-1622.	3.7	40
163	Long-Term Outcome of Endoscopic Balloon Dilatation for Strictures in Patients with Crohn's Disease. <i>Digestion</i> , 2018, 98, 26-32.	2.3	12
164	Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. <i>Current Gastroenterology Reports</i> , 2018, 20, 18.	2.5	29
165	Vedolizumab for the treatment of Crohn's disease. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 179-189.	3.0	6
166	A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 227-234.	1.9	6
167	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 452-456.	0.9	22
168	Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 542-549.e1.	4.4	40

#	ARTICLE	IF	CITATIONS
169	Association of Vedolizumab Level, Anti-Drug Antibodies, and $\hat{I}\pm 4\hat{I}^{27}$ Occupancy With Response in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 697-705.e7.	4.4	103
170	Efficacy and Safety of Adalimumab in Pediatric Ulcerative Colitis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 920-925.	1.8	20
171	Inflammatory bowel disease patients experiencing a loss of response to infliximab regain long-term response after undergoing granulocyte/monocyte apheresis: A case series. <i>Cytokine</i> , 2018, 103, 25-28.	3.2	17
172	A Survey Study of Gastroenterologists'™ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 191-197.	1.9	33
173	Proactive Infliximab Monitoring Following Reactive Testing is Associated With Better Clinical Outcomes Than Reactive Testing Alone in Patients With Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 804-810.	1.3	91
174	Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 631-637.	2.8	11
175	Secondary Loss of Response to Infliximab in Pediatric Crohn Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2018, 66, 637-640.	1.8	5
176	Anti-™Infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 346-355.	3.7	41
177	Defining an Optimal Adherence Threshold for Patients Taking Subcutaneous Anti-TNFs for Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2018, 113, 276-282.	0.4	32
178	Fourteen-Year Anti-TNF Therapy in Crohn's™ Disease Patients: Clinical Characteristics and Predictive Factors. <i>Digestive Diseases and Sciences</i> , 2018, 63, 204-208.	2.3	11
179	External Evaluation of Population Pharmacokinetic Models of Infliximab in Patients With Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 120-129.	2.0	12
180	Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. <i>World Journal of Gastroenterology</i> , 2018, 24, 2457-2467.	3.3	61
181	Novel treatments for inflammatory bowel disease. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 20-27.	1.7	33
182	Management of inflammatory bowel disease. <i>Medical Journal of Australia</i> , 2018, 209, 318-323.	1.7	58
183	Factors predicting the therapeutic response to infliximab during maintenance therapy in Japanese patients with Crohn's™ disease. <i>PLoS ONE</i> , 2018, 13, e0204632.	2.5	20
184	Individualized Dosing of Therapeutic Monoclonal Antibodies™a Changing Treatment Paradigm?. <i>AAPS Journal</i> , 2018, 20, 99.	4.4	29
185	An increased Bax/Bcl™2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. <i>United European Gastroenterology Journal</i> , 2018, 6, 1074-1081.	3.8	24
186	Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study. <i>Intestinal Research</i> , 2018, 16, 223.	2.6	10

#	ARTICLE	IF	CITATIONS
187	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2461-2467.	1.9	50
188	Therapeutic drug monitoring of vedolizumab in inflammatory bowel disease: current data and future directions. Therapeutic Advances in Gastroenterology, 2018, 11, 175628481877278.	3.2	38
189	Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Alimentary Pharmacology and Therapeutics, 2018, 48, 333-339.	3.7	14
190	Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opinion on Investigational Drugs, 2018, 27, 595-599.	4.1	57
191	How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 797-810.	3.0	30
192	A New Venue of TNF Targeting. International Journal of Molecular Sciences, 2018, 19, 1442.	4.1	96
193	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opinion on Investigational Drugs, 2018, 27, 623-629.	4.1	4
194	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2018, 12, 1079-1088.	1.3	50
195	Association Between Infliximab Drug and Antibody Levels and Therapy Outcome in Pediatric Inflammatory Bowel Diseases. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 507-512.	1.8	25
196	Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. Inflammatory Bowel Diseases, 2019, 25, 172-179.	1.9	24
197	The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy. Inflammatory Bowel Diseases, 2019, 25, 568-579.	1.9	51
198	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	1.3	958
199	Achieving Mucosal Healing in Inflammatory Bowel Diseases: Which Drug Concentrations Need to Be Targeted?. Clinical Pharmacology and Therapeutics, 2019, 106, 945-954.	4.7	10
200	Development of quality measures for use of self-injectable biologic therapy in inflammatory bowel disease: An integrated specialty pharmacy initiative. American Journal of Health-System Pharmacy, 2019, 76, 1296-1304.	1.0	7
201	Earlier discontinuation of TNF- $\alpha$ inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects. Alimentary Pharmacology and Therapeutics, 2019, 50, 386-396.	3.7	21
202	Therapeutic drug monitoring-based dosing of TNF inhibitors in inflammatory bowel disease: the way forward?. Expert Review of Clinical Pharmacology, 2019, 12, 885-891.	3.1	8
203	Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients. Drug Development Research, 2019, 80, 831-836.	2.9	7
204	A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD. Inflammatory Bowel Diseases, 2020, 26, 150-157.	1.9	4

#	ARTICLE	IF	CITATIONS
205	Inflammatory bowel disease: long-term therapeutic challenges. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1049-1063.	3.0	8
206	Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2020, 26, 1276-1282.	1.9	4
207	Insights into the role of cannabis in the management of inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481987097.	3.2	25
208	Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?. Current Pharmaceutical Design, 2019, 25, 25-31.	1.9	9
209	High anti-TNF alpha drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1220-1225.	1.5	6
210	Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum. Journal of Immunological Methods, 2019, 474, 112672.	1.4	5
211	Causes of Treatment Failure in Children With Inflammatory Bowel Disease Treated With Infliximab. Journal of Pediatric Gastroenterology and Nutrition, 2019, 68, 37-44.	1.8	41
212	Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2019, 13, 976-981.	1.3	104
213	Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clinical and Experimental Gastroenterology, 2019, Volume 12, 179-191.	2.3	15
214	Small-molecule agents for the treatment of inflammatory bowel disease. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2034-2041.	2.2	11
215	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Alimentary Pharmacology and Therapeutics, 2019, 50, 40-53.	3.7	46
216	Positive pharmacokinetic effect of azathioprine co-medication on infliximab trough levels is dose-dependent. Digestive and Liver Disease, 2019, 51, 1112-1116.	0.9	7
217	Can Magnetic Resonance Enterography (MRE) replace ileo-colonoscopy for evaluating disease activity in Crohn's disease? Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 38-39, 101621.	2.4	12
218	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	4.4	214
219	Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis. Journal of Crohn's and Colitis, 2019, 13, 1527-1536.	1.3	2
220	Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Optimising Therapeutic Effectiveness of Biologics. , 2019, , 243-255.		2
221	Effective Use of the Laboratory in the Management of Patients with Inflammatory Bowel Diseases. Gastroenterology Clinics of North America, 2019, 48, 237-258.	2.2	3
222	Development of a C1q-immobilized (Cim) assay to measure total antibodies to infliximab and its clinical relevance in patients with inflammatory bowel disease. Cytokine, 2019, 120, 54-61.	3.2	2

#	ARTICLE	IF	CITATIONS
223	Why do we need to improve monitoring of patients with inflammatory bowel disease (IBD) on biologic treatment?. Expert Opinion on Biological Therapy, 2019, 19, 907-918.	3.1	6
224	Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease. Expert Opinion on Investigational Drugs, 2019, 28, 473-479.	4.1	30
225	ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1727-1735.	2.8	9
226	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. The Lancet Gastroenterology and Hepatology, 2019, 4, 341-353.	8.1	431
227	Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With Infliximab. Inflammatory Bowel Diseases, 2019, 25, 1805-1812.	1.9	30
228	Infliximab therapy intensification upon loss of response: Is there an optimal trough level?. Digestive and Liver Disease, 2019, 51, 1106-1111.	0.9	10
229	Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Reports in Gastroenterology, 2019, 13, 37-49.	0.6	8
230	A Surface Plasmon Resonance-based assay to measure serum concentrations of therapeutic antibodies and anti-drug antibodies. Scientific Reports, 2019, 9, 2064.	3.3	53
231	Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2019, 25, 1357-1366.	1.9	5
232	Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflammatory Bowel Diseases, 2019, 25, 1532-1540.	1.9	16
233	Pharmacodynamic Monitoring of Biological Therapies in Chronic Inflammatory Diseases. Therapeutic Drug Monitoring, 2019, 41, 131-141.	2.0	6
234	UEG Week 2019 Poster Presentations. United European Gastroenterology Journal, 2019, 7, 189-1030.	3.8	6
235	Loss of response to scheduled infliximab therapy for Crohn's disease in adults: A systematic review and meta-analysis. Journal of Digestive Diseases, 2019, 20, 65-72.	1.5	21
236	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2019, 13, 539-540.	1.3	4
237	Management of Paediatric Patients With Medically Refractory Crohn's Disease Using Ustekinumab: A Multi-Centred Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 578-584.	1.3	43
238	Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring. Alimentary Pharmacology and Therapeutics, 2019, 49, 147-154.	3.7	43
239	Characteristics of biological therapy in pediatric patients with Crohn's disease. Expert Opinion on Biological Therapy, 2019, 19, 181-196.	3.1	5
240	Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease. Expert Opinion on Biological Therapy, 2019, 19, 89-98.	3.1	31



#	ARTICLE	IF	CITATIONS
241	A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. Inflammatory Bowel Diseases, 2019, 25, 820-830.	1.9	76
242	Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort. Internal Medicine Journal, 2019, 49, 753-760.	0.8	6
243	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. Clinical Immunology, 2019, 206, 9-14.	3.2	63
244	Utilidad de las concentraciones s�ricas de adalimumab como predictores de adherencia al tratamiento. Reumatolog�a Cl�nica, 2020, 16, 32-37.	0.5	1
245	Clinical utility of serum concentrations of adalimumab as predictor of treatment adherence. Reumatolog�a Cl�nica (English Edition), 2020, 16, 32-37.	0.3	0
246	Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. Journal of the Canadian Association of Gastroenterology, 2020, 3, 74-82.	0.3	6
247	Efficacy of enteral nutrition in patients with Crohn's disease on maintenance anti-TNF-alpha antibody therapy: a meta-analysis. Journal of Gastroenterology, 2020, 55, 133-141.	5.1	17
248	Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study. Clinical Pharmacology and Therapeutics, 2020, 107, 1189-1199.	4.7	24
249	Anti-MADCAM therapy for ulcerative colitis. Expert Opinion on Biological Therapy, 2020, 20, 437-442.	3.1	9
250	Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 310-317.	1.8	17
251	Predictors of Infliximab Trough Concentrations in Inflammatory Bowel Disease Patients Using a Repeated-Measures Design. Therapeutic Drug Monitoring, 2020, 42, 102-110.	2.0	8
252	Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary. Digestive and Liver Disease, 2020, 52, 274-280.	0.9	5
253	Improving Post-Induction Antitumor Necrosis Factor Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 48-54.	1.8	7
254	Infliximab trough levels: A comparison between the Quantum Blue Infliximab assay and the established ELISA. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1302-1306.	2.8	5
255	The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta. Journal of the Canadian Association of Gastroenterology, 2020, 3, 234-242.	0.3	14
256	Biological therapy in pediatric age. Pharmacological Research, 2020, 161, 105120.	7.1	10
257	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2021, 66, 3548-3554.	2.3	8
258	Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab. Crohn's & Colitis 360, 2020, 2, .	1.1	1



#	ARTICLE	IF	CITATIONS
259	A 3â€­year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1165-1175.	2.4	30
260	Evidence Supporting High-Dose Use of Biologics in Clinical Practice. <i>Current Treatment Options in Gastroenterology</i> , 2020, 18, 408-422.	0.8	2
261	Clinical value of CT-P13 trough levels, an infliximab biosimilar, in the management of inflammatory bowel disease. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 475-480.	0.2	0
262	Laparoscopic bowel resection combined with infliximab treatment (LaRIC) versus infliximab for terminal ileitis in Crohn's disease: a randomised, controlled, open-label trial. <i>BMJ Open</i> , 2020, 10, e038429.	1.9	1
263	Proactive Drug Monitoring Is Associated With Higher Persistence to Infliximab and Adalimumab Treatment and Lower Healthcare Utilization Compared With Reactive and Clinical Monitoring. <i>Crohn's &amp; Colitis</i> 360, 2020, 2, otaa050.	1.1	13
264	TNF-Alpha Blockers in Inflammatory Bowel Diseases: Practical Recommendations and a User's Guide: An Update. <i>Digestion</i> , 2020, 101, 16-26.	2.3	46
265	Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1579-1582.	1.6	9
266	MicroRNA Biomarkers in IBDâ€­Differential Diagnosis and Prediction of Colitis-Associated Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7893.	4.1	64
267	Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 388-397.	1.4	5
268	The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies. <i>Frontiers in Immunology</i> , 2020, 11, 1951.	4.8	102
269	Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094117.	3.2	7
270	Current review of the management of fistulising perianal Crohn's disease. <i>Frontline Gastroenterology</i> , 2021, 12, 515-523.	1.8	9
271	Rapid test detection of anti-infliximab antibodies: performance comparison with three different immunoassays. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096579.	3.2	9
272	Impact of comorbidities on anti-TNF response and relapse in patients with inflammatory bowel disease: the VERNE study. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000351.	2.7	6
273	Complementary and alternative medications in the management of inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092755.	3.2	15
274	An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease. <i>Indian Journal of Gastroenterology</i> , 2020, 39, 176-185.	1.4	15
275	Endoscopic Activity and Serum TNF-Î± Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1669-1681.	1.9	8
276	Incidence of suboptimal response to tumor necrosis factor antagonist therapy in inflammatory bowel disease in newly industrialised countries: The EXPLORE study. <i>Digestive and Liver Disease</i> , 2020, 52, 869-877.	0.9	11

#	ARTICLE	IF	CITATIONS
277	A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1342-1352.	3.7	11
278	A 12-month pilot study outcomes of vagus nerve stimulation in Crohn's disease. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13911.	3.0	76
279	Efficacy of Granulocyte and Monocyte Adsorptive Apheresis in Patients With Inflammatory Bowel Disease Showing Lost Response to Infliximab. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1264-1273.	1.3	16
280	Persistence, Dose Titration, and Health Care Resource Utilization Among Crohn's Disease Patients Treated With Ustekinumab: A Real-World Analysis in the United States. <i>Advances in Therapy</i> , 2020, 37, 2127-2143.	2.9	18
281	Optimizing Antitumor Necrosis Factor Treatment in Pediatric Inflammatory Bowel Disease With Therapeutic Drug Monitoring. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 12-18.	1.8	5
282	The shining DIAMOND for evidence-based treatment strategies for Crohn's disease. <i>Journal of Gastroenterology</i> , 2020, 55, 824-832.	5.1	1
283	Real-world use of therapeutic drug monitoring of CT-P13 in patients with inflammatory bowel disease: A 12-month prospective observational cohort study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 609-618.	1.5	4
284	The Dual Role of Reactive Oxygen Species-Generating Nicotinamide Adenine Dinucleotide Phosphate Oxidases in Gastrointestinal Inflammation and Therapeutic Perspectives. <i>Antioxidants and Redox Signaling</i> , 2020, 33, 354-373.	5.4	28
285	Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 612-628.	3.7	49
286	Serum Biomarkers for Inflammatory Bowel Disease. <i>Frontiers in Medicine</i> , 2020, 7, 123.	2.6	104
287	Prediction of treatment failure during infliximab induction therapy in inflammatory bowel disease patients based on pharmacokinetic and pharmacodynamic modeling. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 150, 105317.	4.0	3
288	Letter: immunogenicity of infliximab "ready for routine prediction? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 813-814.	3.7	0
289	Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 104-110.	4.4	60
290	UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2021, 12, 22-29.	1.8	11
291	Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 106-122.	1.9	14
292	Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 145-154.	1.5	61
293	Efficacy and tolerability of infliximab retreatment in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110419.	2.5	6
294	The Polymorphisms of Interleukin-12B Gene and Susceptibility to Inflammatory Bowel Diseases: A Meta-analysis and Trial Sequential Analysis. <i>Immunological Investigations</i> , 2021, 50, 987-1006.	2.0	4

#	ARTICLE	IF	CITATIONS
295	Impact of infliximab therapeutic drug level monitoring on outcomes of patients with inflammatory bowel disease: A real-world experience from a Middle Eastern cohort. Arab Journal of Gastroenterology, 2021, 22, 66-72.	0.9	1
296	Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases. Frontiers in Neuroscience, 2021, 15, 650971.	2.8	72
297	Advances in the optimization of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF- $\alpha$ antagonists. Expert Opinion on Biological Therapy, 2021, 21, 539-548.	3.1	5
298	Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease. Korean Journal of Internal Medicine, 2021, 36, S9-S17.	1.7	6
299	De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months. Digestive Diseases and Sciences, 2022, 67, 259-262.	2.3	4
300	Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease. Advances in Therapy, 2021, 38, 2339-2352.	2.9	3
301	Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterology & Hepatology, 2021, 44, 312-319.	0.5	11
302	The Role of microRNAs in Development of Colitis-Associated Colorectal Cancer. International Journal of Molecular Sciences, 2021, 22, 3967.	4.1	25
303	Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterology & Hepatology (English Edition), 2021, 44, 312-319.	0.1	0
304	Ustekinumab for Crohn's Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 1920-1930.	1.3	22
305	The brain-gut axis, inflammatory bowel disease and bioelectronic medicine. International Immunology, 2021, 33, 349-356.	4.0	6
306	JAK1 inhibition and inflammatory bowel disease. Rheumatology, 2021, 60, ii45-ii51.	1.9	27
307	Quality Improvement Methodology Optimizes Infliximab Levels in Pediatric Patients with Inflammatory Bowel Disease. Pediatric Quality & Safety, 2021, 6, e400.	0.8	2
308	Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease. Gastroenterology & Hepatology (English Edition), 2021, 44, 337-345.	0.1	0
309	Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease. Gastroenterology & Hepatology, 2021, 44, 337-345.	0.5	2
310	Identification of anti-inflammatory compounds from Zhongjing formulae by knowledge mining and high-content screening in a zebrafish model of inflammatory bowel diseases. Chinese Medicine, 2021, 16, 42.	4.0	10
311	Capsular polysaccharide correlates with immune response to the human gut microbe <i>Ruminococcus gnavus</i> . Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	66
312	Patient Derived Colonoids as Drug Testing Platforms—Critical Importance of Oxygen Concentration. Frontiers in Pharmacology, 2021, 12, 679741.	3.5	8

#	ARTICLE	IF	CITATIONS
313	Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 2132.	2.4	11
314	The Great Debate With IBD Biosimilars. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	1.1	1
315	Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2021, 73, e57-e62.	1.8	17
316	Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2011-2021.	1.3	20
317	<i>Lactobacilli</i> sp. mixture alleviates LPS-induced inflammation in Caco-2 intestinal cell line. <i>Archiva Zootechnica</i> , 2021, 24, 93-106.	0.4	0
318	Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 675194.	4.1	18
319	Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2021, 15, 588-598.	2.9	4
320	Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 3387.	2.4	16
321	Management Decisions in Crohn's Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	1.1	1
322	Targeting sorting nexin 10 improves mouse colitis via inhibiting PIKfyve-mediated TBK1/c-Rel signaling activation. <i>Pharmacological Research</i> , 2021, 169, 105679.	7.1	3
323	Real-World Experience With Proactive Therapeutic Drug Monitoring During Infliximab Reintroduction. <i>Crohn's &amp; Colitis</i> 360, 2021, 3, .	1.1	2
324	Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNF $\pm$ used for the treatment of IBD: Results from the VERNE study. <i>Digestive and Liver Disease</i> , 2022, 54, 76-83.	0.9	8
325	Twenty-five years of biologics in IBD: What's all the hype about?. <i>Journal of Internal Medicine</i> , 2021, 290, 806-825.	6.0	15
326	Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. <i>Gut and Liver</i> , 2022, 16, 157-170.	2.9	8
327	Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNF $\pm$ therapy in inflammatory bowel disease patients: a report from the epi-IIRN. <i>Gut</i> , 2022, 71, 287-295.	12.1	12
328	Preclinical development of a bispecific TNF $\pm$ /IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease. <i>Scientific Reports</i> , 2021, 11, 19422.	3.3	12
329	Microbial Metabolism of Inflammatory Bowel Disease Drugs: Current Evidence and Clinical Implementations. <i>Gastroenterology</i> , 2022, 162, 4-8.	1.3	3
330	Bacterial Translocation as Inflammatory Driver in Crohn's Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 703310.	3.7	25

#	ARTICLE	IF	CITATIONS
331	Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?. Inflammatory Intestinal Diseases, 2022, 7, 50-58.	1.9	24
332	Loss of response to anti-TNF $\alpha$ agents depends on treatment duration in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 1298-1308.	3.7	24
333	Long-term Outcomes after the Discontinuation of Anti-Tumor Necrosis Factor- $\alpha$ Therapy in Patients with Inflammatory Bowel Disease under Clinical Remission: A Korean Association for the Study of Intestinal Disease Multicenter Study. Gut and Liver, 2021, 15, 752-762.	2.9	9
334	Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clinical and Translational Science, 2022, 15, 172-181.	3.1	18
335	Therapeutic drug monitoring in inflammatory bowel disease: The dawn of reactive monitoring. World Journal of Gastroenterology, 2021, 27, 6231-6247.	3.3	13
336	Monosexual Cercariae of Schistosoma japonicum Infection Protects Against DSS-Induced Colitis by Shifting the Th1/Th2 Balance and Modulating the Gut Microbiota. Frontiers in Microbiology, 2020, 11, 606605.	3.5	8
337	Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. Gastroenterología Y Hepatología, 2020, 43, 1-57.	0.5	24
338	Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Infliximab in Pediatric Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, 763-776.	1.8	27
339	Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS ONE, 2017, 12, e0175099.	2.5	32
340	DISCONTINUATION RATES FOLLOWING A SWITCH FROM A REFERENCE TO A BIOSIMILAR BIOLOGIC IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Arquivos De Gastroenterologia, 2020, 57, 232-243.	0.8	9
341	Contribution of infliximab population pharmacokinetic model for dose optimization in ulcerative colitis patients. Revista Espanola De Enfermedades Digestivas, 2015, , .	0.3	1
342	Cost-effectiveness analysis of fecal microbiota transplantation for inflammatory bowel disease. Oncotarget, 2017, 8, 88894-88903.	1.8	33
343	JAK Inhibition as a Therapeutic Strategy for Inflammatory Bowel Disease. Current Drug Metabolism, 2020, 21, 247-255.	1.2	4
344	Evaluation of cytokine levels as putative biomarkers to predict the pharmacological response to biologic therapy in inflammatory bowel diseases. Minerva Gastroenterologica E Dietologica, 2020, 65, 298-308.	2.2	10
345	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- $\alpha$ ) inhibitors [LISA-TRACKER $\text{\textcircled{R}}$ enzyme-linked immunosorbent assay (ELISA) kits, TNF- $\alpha$ -Blocker ELISA kits and Promonitor $\text{\textcircled{R}}$ ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technology Assessment, 2016, 20, 1-288.	2.8	27
346	Low rates of adherence for tumor necrosis factor- $\alpha$ inhibitors in Crohn's disease and rheumatoid arthritis: Results of a systematic review. World Journal of Gastroenterology, 2013, 19, 4344.	3.3	66
347	Immunogenetic biomarkers in inflammatory bowel diseases: Role of the IBD3 region. World Journal of Gastroenterology, 2014, 20, 15037.	3.3	16
348	Integrin antagonists are effective and safe for Crohn's disease: A meta-analysis. World Journal of Gastroenterology, 2015, 21, 4744-4749.	3.3	7

#	ARTICLE	IF	CITATIONS
349	Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease. World Journal of Gastroenterology, 2020, 26, 4055-4075.	3.3	51
350	What is the role of vedolizumab in the era of anti-TNF agents?. Annals of Translational Medicine, 2014, 2, 4.	1.7	2
351	Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease. Gut and Liver, 2017, 11, 55-61.	2.9	29
352	Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. Gut and Liver, 2019, 13, 604-616.	2.9	90
353	Intestinal Stricture in Crohn's Disease. Intestinal Research, 2015, 13, 19.	2.6	76
354	The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, 295-301.	1.6	1
355	Interventions to improve medication adherence in inflammatory bowel disease: A systematic review. Patient Education and Counseling, 2022, 105, 1731-1742.	2.2	6
356	“My Medications Are Not Working, What Can I Try Now for My Crohn's Disease?” Options for Refractory Crohn's Disease. , 2015, , 99-106.		0
357	Biologics for Ulcerative Colitis: Status of the Art and General Considerations. Annals of Colorectal Research, 2016, 5, .	0.1	1
358	Biologics for Ulcerative Colitis: Status of the Art and General Considerations. Annals of Colorectal Research, 2016, Inpress, .	0.1	0
359	Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. , 2017, , 417-424.		0
360	EFFICACY AND SAFETY OF VEDOLIZUMAB IN CROHN'S DISEASE (review). Koloproktologia, 2017, , 71-79.	0.6	0
361	Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients?. Annals of Translational Medicine, 2018, 6, 278-278.	1.7	2
362	Validation of a population pharmacokinetic model of adalimumab in a cohort of patients with inflammatory bowel disease. Revista Espanola De Enfermedades Digestivas, 2019, 111, 431-436.	0.3	1
363	Medical Management 3: Biologicals. , 2019, , 91-98.		0
364			



#	ARTICLE	IF	CITATIONS
368	Utilidad clínica de la determinación de niveles de CT-P13, biosimilar de infliximab, en el control de la enfermedad inflamatoria intestinal. Medicina Clínica, 2020, 154, 475-480.	0.6	0
369	Present and Future Therapeutic Approaches to Barrier Dysfunction. Frontiers in Nutrition, 2021, 8, 718093.	3.7	21
370	Multi-alleles predict primary non-response to infliximab therapy in Crohn's disease. Gastroenterology Report, 2021, 9, 427-434.	1.3	0
371	Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. Journal of Clinical Gastroenterology, 2021, 55, 195-206.	2.2	11
372	Induction and maintenance therapy with vedolizumab, a novel biologic therapy for ulcerative colitis. Gastroenterology and Hepatology, 2014, 10, 64-6.	0.1	1
373	Infliximab dosing patterns in a sample of patients with Crohn's disease: results from a medical chart review. American Health and Drug Benefits, 2014, 7, 87-93.	0.5	5
374	Therapeutic drug monitoring in inflammatory bowel disease. Annals of Gastroenterology, 2014, 27, 304-312.	0.6	33
376	Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach. Gastroenterology and Hepatology, 2015, 11, 48-55.	0.1	3
377	Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. Gastroenterology and Hepatology, 2014, 10, 793-800.	0.1	4
378	Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease. Gastroenterology and Hepatology, 2014, 10, 478-489.	0.1	1
379	Improving IBD Care: A Personalized Approach to Management. Gastroenterology and Hepatology, 2018, 14, 1-20.	0.1	8
380	Vedolizumab-Induced De Novo Extraintestinal Manifestations. Gastroenterology and Hepatology, 2020, 16, 75-81.	0.1	3
381	Target-Based Small Molecule Drug Discovery Towards Novel Therapeutics for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, S38-S62.	1.9	14
382	Differential serum-intestinal dynamics of infliximab and adalimumab in inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2021, , .	1.3	0
384	Host transcriptome signatures in human faecal-washes predict histological remission in patients with IBD. Gut, 2022, 71, 1988-1997.	12.1	6
385	Biologic agents and small molecules – mechanism of action. Seminars in Colon and Rectal Surgery, 2022, , 100861.	0.3	0
386	Methotrexate in inflammatory bowel disease: A primer for gastroenterologists. Saudi Journal of Gastroenterology, 2022, 28, 250.	1.1	5
387	Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis?. Inflammatory Bowel Diseases, 2022, 28, 1658-1666.	1.9	2



#	ARTICLE	IF	CITATIONS
388	Induction Efficacy of Upadacitinib in Therapy-Refractory Crohn's Disease: A Retrospective Case Series. Clinical Gastroenterology and Hepatology, 2023, 21, 532-534.e3.	4.4	3
389	Discontinuation of Azathioprine could be considered in pediatric patients with Crohn's disease who have sustained clinical and deep remission. Scientific Reports, 2022, 12, 507.	3.3	1
390	Current Therapy in Inflammatory Bowel Disease: Why and How We Need to Change?. European Medical Journal Innovations, 0, , 40-49.	2.0	5
391	Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110709.	3.2	6
392	A Subject-Tailored Variability-Based Platform for Overcoming the Plateau Effect in Sports Training: A Narrative Review. International Journal of Environmental Research and Public Health, 2022, 19, 1722.	2.6	22
393	Effectiveness of ustekinumab in patients with refractory Crohn's disease: a multicentre real-life study in Italy. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482110724.	3.2	14
394	Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210833.	3.2	0
395	Comparison of Ustekinumab Trough Concentrations Measured by 2 ELISA Kits and Evaluation of Clinical Response in Crohn's Disease. Therapeutic Drug Monitoring, 2022, 44, 535-542.	2.0	2
396	Subcutaneous injection of infliximab <scp>CTAEP13</scp> results in stable drug levels within 14-day treatment cycle in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2022, 56, 77-83.	3.7	11
398	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 2607-2618.e14.	4.4	13
400	BMI is important in predicting the loss of response in inflammatory bowel disease patients on tumour necrosis factor- $\alpha$ inhibitors. European Journal of Gastroenterology and Hepatology, 2022, 34, 622-629.	1.6	3
401	Predictor of primary response to antitumor necrosis factor- $\alpha$ therapy for inflammatory bowel disease: a single-center observational study. European Journal of Gastroenterology and Hepatology, 2022, Publish Ahead of Print, .	1.6	1
402	Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatrics, 2022, 22, 175.	1.7	6
403	ScRNA-seq identified the metabolic reprogramming of human colonic immune cells in different locations and disease states. Biochemical and Biophysical Research Communications, 2022, 604, 96-103.	2.1	3
404	Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells. International Immunopharmacology, 2022, 107, 108698.	3.8	23
405	Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021). Al'manah KliniĖskoj Mediciny, 2021, 49, 485-495.	0.3	0
406	Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry. Journal of Crohn's and Colitis, 2021, , .	1.3	6
407	Infliximab for Anoperineal Lesions in Crohn's Disease: Remission Appears to be Based on Rapid Combination Therapy at High Doses. Journal of Coloproctology, 0, , .	0.1	0

#	ARTICLE	IF	CITATIONS
408	An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. Journal of Clinical Medicine, 2022, 11, 2302.	2.4	25
409	Safety of sequential biological therapy in inflammatory bowel disease: results from a tertiary referral Centre. Alimentary Pharmacology and Therapeutics, 2022, , .	3.7	1
419	Comparison of the Pharmacokinetics of CT-P13 Between Crohn's Disease and Ulcerative Colitis. Journal of Clinical Gastroenterology, 2022, Publish Ahead of Print, .	2.2	0
420	Outcomes after double switching from originator Infliximab to biosimilar CT-P13 and biosimilar SB2 in patients with inflammatory bowel disease: a 12-month prospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 887-899.	3.7	19
421	Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF- $\alpha$ : results from the ENEIDA registry. Alimentary Pharmacology and Therapeutics, 2021, 53, 1021-1029.	3.7	8
422	Anti-TNF therapy and immunogenicity in inflammatory bowel diseases: a translational approach.. American Journal of Translational Research (discontinued), 2021, 13, 13916-13930.	0.0	0
423	Efficacy of Intravenous Ustekinumab Reinduction in Patients With Crohn's Disease With a Loss of Response. Journal of the Canadian Association of Gastroenterology, 2022, 5, 208-213.	0.3	6
424	A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis. Frontiers in Medicine, 2022, 9, 872831.	2.6	5
425	Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases. Autoimmunity, 2022, 55, 275-284.	2.6	3
426	Real clinical practice of complicated Crohn's disease treatment with ustekinumab: clinical case presentation. Meditsinskiy Sovet, 2022, , 116-122.	0.5	0
427	Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis. Intestinal Research, 2023, 21, 61-87.	2.6	17
428	Multi-model averaging improves the performance of model-guided infliximab dosing in patients with inflammatory bowel diseases. CPT: Pharmacometrics and Systems Pharmacology, 2022, 11, 1045-1059.	2.5	9
429	Analysis of the Clinical Efficacy of Infliximab in the Treatment of Steroid-Refractory Ulcerative Colitis in Children. Iranian Journal of Pediatrics, 2022, In Press, .	0.3	0
430	Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Frontiers in Medicine, 0, 9, .	2.6	14
431	Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn's disease: a KASID prospective multicenter study. Intestinal Research, 2023, 21, 137-147.	2.6	1
432	Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies. BioDrugs, 2022, 36, 625-637.	4.6	18
433	An autologous colonic organoid-derived monolayer model to study immune: bacterial interactions in Crohn's disease patients. Clinical and Translational Immunology, 2022, 11, .	3.8	8
434	In vivo self-assembled siRNA as a modality for combination therapy of ulcerative colitis. Nature Communications, 2022, 13, .	12.8	11

#	ARTICLE	IF	CITATIONS
435	Electrical neuromodulation therapy for inflammatory bowel disease. World Journal of Gastrointestinal Pathophysiology, 0, 13, 128-142.	1.0	1
436	A Systematic Review on the Interest of Drug-tolerant Assay in the Monitoring of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2023, 17, 633-643.	1.3	6
437	Neutrophils in Intestinal Inflammation: What We Know and What We Could Expect for the Near Future. Gastrointestinal Disorders, 2022, 4, 263-276.	0.8	4
438	Efficacy and safety of vedolizumab for inflammatory bowel diseases: A systematic review and meta-analysis of randomized controlled trials. Medicine (United States), 2022, 101, e30590.	1.0	5
439	Korean clinical practice guidelines on biologics for moderate to severe Crohn's disease. Intestinal Research, 2023, 21, 43-60.	2.6	11
440	Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis. Inflammatory Bowel Diseases, 2023, 29, 1633-1647.	1.9	8
441	Targeting Mucosal Healing: Optimising Results with Early Appropriate Therapy in Crohn's Disease. European Medical Journal (Chelmsford, England), 0, , 52-57.	3.0	0
442	Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn's Disease patients: A retrospective analysis using German claims data. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482211305.	3.2	2
443	The IBD Management Puzzle: Do We Have All the Pieces?. European Medical Journal (Chelmsford,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	0
444	Emerging drugs for the treatment of inflammatory bowel disease. Expert Opinion on Emerging Drugs, 2022, 27, 369-377.	2.4	3
445	Impact of thiopurine dose in anti-tumor necrosis factor combination therapy on outcomes in inflammatory bowel disease. Annals of Gastroenterology, 2022, , .	0.6	1
446	Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study. Future Pharmacology, 2022, 2, 669-680.	1.8	0
447	Treatment with adalimumab 80Âmg every other week in inflammatory bowel disease: Results of treatment intensification in clinical practice. Crohn's & Colitis 360, 0, , .	1.1	0
448	Influence of <i>HLADQA1*05</i> Genotype in Adults With Inflammatory Bowel Disease and Anti-TNF Treatment With Proactive Therapeutic Drug Monitoring: A Retrospective Cohort Study. Inflammatory Bowel Diseases, 2023, 29, 1586-1593.	1.9	7
449	IBD disease-modifying therapies: insights from emerging therapeutics. Trends in Molecular Medicine, 2023, 29, 241-253.	6.7	17
450	Therapeutic Potential of Bioactive Components from Scutellaria baicalensis Georgi in Inflammatory Bowel Disease and Colorectal Cancer: A Review. International Journal of Molecular Sciences, 2023, 24, 1954.	4.1	17
451	Cassane diterpenoid ameliorates dextran sulfate sodium-induced experimental colitis by regulating gut microbiota and suppressing tryptophan metabolism. Frontiers in Immunology, 0, 13, .	4.8	3
453	Selective JAK1 inhibitors for the treatment of inflammatory bowel disease. , 2023, 245, 108402.		4

#	ARTICLE	IF	CITATIONS
454	The Impact of Intermediate Antidrug Antibodies to Infliximab and Adalimumab on Clinical Outcomes in Patients with Crohn's Disease or Ulcerative Colitis. European Medical Journal (Chelmsford, England), 0, , 84-93.	3.0	0
455	Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial. Clinical and Translational Gastroenterology, 2023, 14, e00549.	2.5	3
456	Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights. Pharmaceuticals, 2023, 16, 324.	3.8	1
457	Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Frontiers in Microbiology, 0, 14, .	3.5	6
458	Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease. International Journal of Colorectal Disease, 2023, 38, .	2.2	5
459	Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease. , 2023, , 445-456.		22
460	Predictive factors of the clinical efficacy of ustekinumab in patients with refractory Crohn's disease: tertiary centers experience in Japan. International Journal of Colorectal Disease, 2023, 38, .	2.2	2
461	Dose Escalation Patterns of Advanced Therapies in Crohn's Disease and Ulcerative Colitis: A Systematic Literature Review. Advances in Therapy, 2023, 40, 2051-2081.	2.9	5
462	Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD). Expert Opinion on Biological Therapy, 0, , 1-10.	3.1	0
463	Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study. Gastroenterology & Hepatology, 2024, 47, 51-62.	0.5	1
464	Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn's disease patients with secondary loss of response. Therapeutic Advances in Gastroenterology, 2023, 16, 175628482311709.	3.2	0
465	Exit strategies in inflammatory bowel disease: Looking beyond anti-tumor necrosis factors. World Journal of Clinical Cases, 0, 11, 2657-2669.	0.8	0
466	Discovery of a novel RIPK2 inhibitor for the treatment of inflammatory bowel disease. Biochemical Pharmacology, 2023, 214, 115647.	4.4	2
467	The role of therapeutic drug monitoring in the management of inflammatory bowel disease. Gastroenterology, Hepatology and Endoscopy Practice, 2023, 3, 72.	0.2	1
468	Efficacy of Early Optimization of Infliximab Guided by Therapeutic Drug Monitoring during Induction: A Prospective Trial. Biomedicines, 2023, 11, 1757.	3.2	1
469	Efficacy and safety of vedolizumab in the treatment of patients with inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 2023, 25, .	1.8	1
470	Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers. Inflammatory Bowel Diseases, 2024, 30, 423-428.	1.9	2
471	The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD. Journal of Clinical Medicine, 2023, 12, 4382.	2.4	0

#	ARTICLE	IF	CITATIONS
472	An in vitro analysis of the interaction between infliximab and granulocyteâ€“monocyte apheresis. GastroenterologÃa Y HepatologÃa, 2023, , .	0.5	2
473	HLA-DQA1*05 and upstream variants of PPARGC1B are associated with infliximab persistence in Japanese Crohnâ€™s disease patients. Pharmacogenomics Journal, 2023, 23, 141-148.	2.0	1
474	Durability of the First Biologic in Patients with Crohnâ€™s Disease: A Nationwide Study from the epi-IRN. Journal of Crohn's and Colitis, 2024, 18, 38-46.	1.3	2
475	A novel role of prognostic nutritional index in predicting the effectiveness of infliximab in Crohn's disease. Annals of Medicine, 2023, 55, .	3.8	0
476	HLA-DQA1*05 Was Not Associated With Primary Nonresponse or Loss of Response to First Anti-TNF in Real-World Inflammatory Bowel Disease Patients. Inflammatory Bowel Diseases, 0, , .	1.9	4
477	Adsorptive cytapheeresis in ulcerative colitis: A nonâ€“pharmacological therapeutic approach revisited. Journal of Clinical Apheresis, 2023, 38, 746-754.	1.3	0
478	Effectiveness and Safety of Ustekinumab for Pediatric Inflammatory Bowel Disease: A Systematic Review. Paediatric Drugs, 2023, 25, 499-513.	3.1	1
479	Neuroimmune Modulation Through Vagus Nerve Stimulation Reduces Inflammatory Activity in Crohnâ€™s Disease Patients: A Prospective Open-label Study. Journal of Crohn's and Colitis, 2023, 17, 1897-1909.	1.3	6
482	APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease. Biomolecules, 2023, 13, 1569.	4.0	1
483	Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohnâ€™s Disease: A Retrospective, International Multicenter Study. Inflammatory Bowel Diseases, 0, , .	1.9	0
484	Interleukin-17 and inflammatory bowel disease: a 2-sample Mendelian randomization study. Frontiers in Immunology, 0, 14, .	4.8	1
485	Comparison between washed microbiota transplantation and infliximab: Medical cost during long-term management in patients with inflammatory bowel disease. Journal of the Chinese Medical Association, 0, , .	1.4	0
486	Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with Crohnâ€™s disease: results from the EVOLVE study. European Journal of Gastroenterology and Hepatology, 2024, 36, 281-291.	1.6	0
487	Predictors of Efficacy of Janus Kinase Inhibitors in Patients Affected by Ulcerative Colitis. Journal of Clinical Medicine, 2024, 13, 766.	2.4	0
488	Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation. Therapeutic Drug Monitoring, 0, , .	2.0	0
490	H<sub>2</sub>Sâ€“Releasing Versatile Montmorillonite Nanoformulation Trilogically Renovates the Gut Microenvironment for Inflammatory Bowel Disease Modulation. Advanced Science, 2024, 11, .	11.2	1
491	Perceptions Toward Established and Novel Dietary Therapies for Crohnâ€™s Disease Management Among Adult Patients: Results From a Questionnaire Survey. Crohn's & Colitis 360, 2024, 6, .	1.1	0
492	Aryl Hydrocarbon Receptor Regulates Muc2 Production Independently of IL-22 during Colitis. International Journal of Molecular Sciences, 2024, 25, 2404.	4.1	0

#	ARTICLE	IF	CITATIONS
493	Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East. Therapeutic Advances in Gastroenterology, 2024, 17, .	3.2	0
494	Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study. Gastroenterology & Hepatology (English Edition), 2024, 47, 51-62.	0.1	0
495	Unmet needs of drugs for irritable bowel syndrome and inflammatory bowel diseases: interest of vagus nerve stimulation and hypnosis. Inflammopharmacology, 2024, 32, 1005-1015.	3.9	0